Filing identity and period
Important entity mismatch: The request identifies Jasper Therapeutics, Inc., but the supplied Form 10-Q is for Amplitude Healthcare Acquisition Corporation, a blank-check company. This summary describes the supplied filing, not a Jasper Therapeutics filing. It covers the unaudited quarter ended March 31, 2020.
Business context
Amplitude was formed to pursue a business combination, with a focus on healthcare targets. It had not begun operations and reported no operating revenue; its activities were formation, public-company costs, and searching for a target. It had until November 22, 2021 to complete a business combination or begin liquidation under the terms described in the filing.
Financial results and liquidity
- Revenue: No operating revenue. The company stated it would not expect operating revenue until after a business combination.
- Profit: Net income was $38,859, comprising $325,348 of trust-account interest, less $228,666 of general and administrative expenses and $57,823 of income-tax provision. Operating loss was $228,666.
- Cash flow: Operating activities used $232,870; investing activities provided $77,310, including cash withdrawn from the trust for franchise taxes. Cash declined by $155,560 to $1,057,195.
- Assets and liquidity: Total assets were $101.8 million, including $100.4 million in trust-account investments and $1.1 million of cash outside the trust. Current assets were $1.39 million versus current liabilities of $171,000.
- Debt and obligations: No long-term debt was reported. The company had a $3.5 million deferred underwriting fee payable if it completed a business combination. Total liabilities were $3.67 million.
- Margins: Not meaningful for this pre-combination company with no operating revenue.
Changes versus prior period
Compared with December 31, 2019, cash outside the trust fell by $155,560, while trust-account investments rose by about $248,000 to $100.4 million. Total liabilities increased by about $60,000, primarily reflecting higher income taxes payable. Stockholders’ equity remained approximately $5.0 million. The filing provides no prior-year comparable-quarter operating results, so year-over-year changes cannot be assessed.
Outlook, risks, and unusual items
- Management expected to use trust funds, less taxes and deferred underwriting commissions, toward a business combination. It said it did not believe additional funds would be needed for planned expenditures, but warned that underestimated search or transaction costs, significant shareholder redemptions, or insufficient funds could require financing or prevent a transaction.
- COVID-19 could adversely affect target businesses and the company’s ability to conduct diligence, travel, meet counterparties, and complete a transaction; the specific impact was not determinable.
- Potential business-combination financing through new equity or debt could dilute shareholders, affect control, or increase leverage and related repayment and covenant risks.
- The underwriters’ over-allotment option expired unexercised on January 6, 2020, and 375,000 founder shares were forfeited.
- A March 2020 related-party consulting agreement provided for due-diligence services at $600 per hour; no fees were paid or owed at quarter-end. The company also reported month-to-month office payments of $3,697 per month to an entity 45% owned by its CEO.
- No legal proceedings or subsequent events requiring adjustment or disclosure were reported. Management concluded disclosure controls were effective and reported no material change in internal controls during the quarter.
Investor facts to verify
- Confirm the issuer: the supplied filing is for Amplitude Healthcare Acquisition Corporation, not Jasper Therapeutics, Inc.
- Verify the trust balance, redemption terms, and November 22, 2021 business-combination deadline against the filed statements and governing documents.
- Review cash available outside the trust and expected transaction costs, including the contingent $3.5 million deferred underwriting fee.
- Assess the impact of COVID-19 and any subsequent developments on the company’s target search and ability to complete a transaction.
- Review dilution and warrant terms, including possible additional securities or debt issued in a business combination.